INTRODUCTION
Recent advances in cancer genetics provide opportunities to improve the prediction of cancer risk, particularly through germline testing for hereditary predisposition.
1,2 However, before the broad adoption of any testing strategy, it is critical to determine differences between theoretic benefit and realworld outcome.
Lynch syndrome is characterized by the development of colorectal (CRC), endometrial, and other cancers, often at a young age. This familial cancer syndrome results from germline mutations of DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6, and PMS2 and causes approximately 1% to 3% of all CRCs. [3] [4] [5] Because these cancers are MMR deficient (MMRD), they display microsatellite instability (MSI) and immunohistochemical loss of relevant MMR proteins. 6 Identifying individuals with Lynch syndrome is important because colonoscopic surveillance of both index patient cases and at-risk relatives reduces CRC mortality, 7, [8] [9] [10] [11] and surgery can prevent gynecologic malignancies. 12 In theory, most CRCs resulting from Lynch syndrome are identifiable through universal screening of all index tumors for MMRD. 4, 9 Immunohistochemical assessment of MMR proteins is a cheap and sensitive screening test in this context 13 ; MSI testing can also be used for screening, although it is less suited to anatomic pathology workflows.
14 The value of either method in identifying Lynch syndrome tumors is significantly limited because 15% of sporadic CRCs also displayMMRDasaresultofsomaticinactivationofthe MLH1 gene by promoter methylation. 15 One approach to excluding these sporadic patient cases with somatic MLH1 inactivation is to confine screening for MMRD to individuals with young-onset CRC or strong family history. Unfortunately, this strategy misses many Lynch syndrome cases. 16 A more recent approach takes advantage of the fact that these sporadic patient cases typically involve V600E BRAF mutations. Such instances could be excluded by restricting germline testing to those patients with MMRD tumors that also lack V600E BRAF mutations, 13 thus increasing the a priori likelihood of Lynch syndrome. 17 Despite the clear benefits of universal MMRD testing in CRC, not all institutions have incorporated this approach into routine care. Possible reasons for this include poor patient uptake of genetic testing and counseling, 2 uncertainty about optimal MMRD testing methodologies, 18, 19 and concerns regarding interpretation of results by end users. In addition, there are ethical and insurance implications for routinely assessing MMR status without patient consent. A further impediment to implementing universal MMRD testing is the paucity of evidence available to inform the decisions of health system administrators and reimbursement agencies. 1, 19 Where such information is available, it has come largely from research settings rather than from routine clinical practice. 1 To date, knowledge is limited regarding the effect that decisions by patients or clinicians have on the ability of universal MMRD screening to detect patient cases of Lynch syndrome.
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To address this issue, we undertook a multicenter prospective study of the real-world implementation of routine MMRD testing of all incident patient cases of CRCs in a health service in Australia serving 1.2 million people. The goal of the study was to determine the frequency of detection of pathogenic mutations of MMR genes in participants and the extent to which decisions of patients or clinicians reduced the effectiveness of this universal molecular screening strategy.
PATIENTS AND METHODS

Setting, Eligibility, and Recruitment
Australia has a publicly funded universal health care system, entitling citizens to subsidized treatment from medical practitioners and fully subsidized treatment in public hospitals. This study drew on all incident CRCs Study schema for universal molecular screening of all newly diagnosed colorectal cancers (CRCs) for Lynch syndrome. The study involved pathologists, surgeons, researchers, and family cancer center staff in different aspects as shown. The schema highlights the two distinct phases of the study, with the second phase (light blue boxes) conducted after patient consent. In phase one (dark blue boxes), all cases of surgically resected CRC assessed within the five pathology laboratories were tested for mismatch repair (MMR) protein loss by immunohistochemistry, supported by microsatellite analysis in all patient cases showing MMR loss (MMRD) or equivocal staining. BRAF mutation testing was performed by the central research laboratory in all MMRD patient cases. Surgeons were asked to invite patients to participate in the study and were also provided with case-specific advice regarding referral to family cancer centers. In the second phase (clear boxes), consenting participants provided clinical information as well as samples for germline testing. Each patient was also asked to provide a research blood or saliva sample for germline mutation testing of MMR genes and asked if he or she wished to be contacted in the event that a germline change in the MMR genes was found. If the patient did wish to be informed, he or she also needed to consent to the release of results to the nominated clinician for repeat genetic testing and counseling as appropriate. (Fig 1, dark blue boxes) . For individuals with MMRD cancers, this allowed assessment of a priori likelihood of Lynch syndrome as either low (both MLH1 loss and BRAF mutation) or high (all other cancers). An advice package (Data Supplement) was subsequently sent to the treating surgeon recommending referral of all patients with high-likelihood cancers to a family cancer center; low-likelihood patient cases were not recommended for referral, except where other circumstances indicated it. Referral decisions were made entirely by the surgeon in consultation with his or her patient, without direct involvement of the research team.
The second phase of the study (Fig 1; light blue boxes) occurred after consent to participate had been obtained from an eligible phase-one participant (age Ͼ18 years; no previous diagnosis of hereditary cancer syndrome). In this postconsent phase, which ran in parallel with the first phase, participants were asked to provide a research blood or saliva sample to detect MMR germline mutations. Participants were also asked to provide relevant clinical information, and their preference regarding disclosure of germline mutation analysis from their research sample (Fig 1) .
Pathologic Assessment of Cancers
CRC specimens at participating centers were staged according to American Joint Committee on Cancer/Union for International Cancer Control guidelines, 21 with immunohistochemical analysis of four MMR proteins (MLH1, PMS2, MSH2, and MSH6; Data Supplement). The exact number of CRC specimens subject to MMR protein immunohistochemistry was not known, because unit-level data were not provided by all pathology laboratories. However, on the basis of throughput and start dates for each laboratory, as well as cancer registry data on CRC in SESIAHS, 20 we estimated 2,100 cancers were reported by these laboratories over the 39-month study period.
Molecular Testing of Tumors
MSI testing was performed on tumors showing loss or equivocal expression of any MMR protein by immunohistochemistry. 22, 23 V600E BRAF mutations were identified by pyrosequencing 24 (Data Supplement). Assay results from the research genetics laboratory were returned to the diagnostic laboratory. For quality assurance, MSI testing was also conducted on 50 randomly selected patient cases showing normal MMR immunohistochemistry (10 each from the five laboratories), and none showed MSI.
Assessment of Germline MMR Status
Patients referred to a family cancer center were offered MMR gene germline testing according to standard clinical practice. If a patient was not referred to a family cancer center, or if the center did not undertake germline testing for any reason, samples obtained in the postconsent phase of the study (research samples) were used for germline testing. Germline testing for mutations in MMR genes was performed and interpreted 25-28 by a diagnostic molecular service (IMVS, Adelaide, South Australia, Australia; Data Supplement). For MLH1, the 5Ј untranslated region was screened for sequence changes and promoter methylation as previously described.
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Statistical Analysis
Demographic data were summarized as mean (Ϯ standard deviation) or frequency (%). Differences among participants in terms of takeup of germline testing were explored using 2 (categorical variables) or unpaired t tests (continuous variables).
Logistic regression was used to predict factors associated with referral to a family cancer center and to estimate the proportion of patients with germline mutations among those in the cohort who did not provide a sample for germline analysis. CIs for the estimates were obtained using the delta method for an individual prediction at fixed (average) values for each group. Abbreviations: CRC, colorectal cancer; MMR, mismatch repair; SD, standard deviation.
‫ء‬
Seven of the 245 patients in this study had synchronous cancers that were also MMR deficient, so only the most advanced tumor was selected for inclusion in this study.
Statistical significance was defined as P Ͻ .05. Analyses were performed using SPSS statistical software (version 20; SPSS, Chicago, IL).
RESULTS
Study Cohort Characteristics
During the preconsent phase of the project, 253 MMRD CRCs (confirmed by immunohistochemistry and MSI testing) were identified among 245 individuals (clinicopathologic characteristics listed in Table 1 ). Of these 245 patients, 194 (79%) consented to participate in the next phase, 143 (58%) provided samples for germline analysis, and 51 (21%) provided medical information but no biologic sample (Appendix Fig A1, online only) . The mean time to consent was 6.6 months (range, 4 to 1,100 days), with 81% consenting within 1 year. Patients providing consent differed from those who did not in that they were younger (age 71.2 Ϯ 12.4 v 77.3 [plusmn 11.1 years; P ϭ .001) and more likely to be male (39.7% v 21.6%; P ϭ .016) but showed no significant differences in tumor stage, location, or immunohistochemical pattern.
MMR Immunohistochemistry
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Abbreviations: MMR, mismatch repair; SD, standard deviation (n ϭ 12), loss of all four MMR proteins (n ϭ 2), and unpaired loss (ie, MLH1/MSH6 or MSH2/PMS2; n ϭ 2). Clinicopathologic correlates for the 194 consenting patients are listed in Table 2 .
Referral to Family Cancer Center
Of the 194 consenting patients, 120 (62%) were designated as having a low likelihood of Lynch syndrome, and the remainder (n ϭ 74; 38%) as having a high likelihood (Appendix Fig A1, online  only) . Referral and attendance of these patients to a family cancer center and performance of germline testing are summarized in Table 3 .
Factors predicting referral to a family cancer center were: high likelihood of Lynch syndrome (odds ratio [OR], 25.5; 95% CI, 6.6 to 97.7; P Ͻ .001), younger age (OR, 1.08; 95% CI, 1.03 to 1.11; P Ͻ .001), and presence of a right-sided tumor (OR, 4.3; 95% CI, 1.1 to 17.3; P ϭ .039). Metastatic disease, family or personal history of cancer, and Jewish heritage were not associated with referral.
Outcomes of Germline Testing
Of the 194 consenting patients, 31 attended a family cancer center, and 27 (87%) undertook germline testing (Table 3) . Of the remaining 167 consenting patients who did not undergo germline testing at a family cancer center, research samples were available from 116 (69%). Of these, 30 (26%) were considered as having a high likelihood of Lynch syndrome, and 86 (74%) were considering as having a low likelihood. More than one quarter of these patients (n ϭ 31; 27%) indicated they did not want to receive the results of the testing or were uncertain whether they wanted the results (n ϭ 25 [29% low likelihood]; n ϭ 6 [20% high likelihood]).
Overall, germline testing was performed in 143 individuals, 27 through a family cancer center and 116 using research samples. Twelve individuals had deleterious germline mutations of MMR genes (8.4%; 95% CI, 4.4% to 14.2%; n ϭ 10 in family cancer center, n ϭ 2 in research), whereas unclassified variants (UCVs) were found in four others (Table 3) . Pathogenic mutations or UCVs were limited to high-likelihood individuals, with pathogenic mutations more common in MSH6-deficient patients (five of 12 patients; 45%) than in MLH1-(three of 12; 27%), MSH2-(two of 12; 18%), or PMS2-deficient patients (two of 12; 18%). The mean age of mutationpositive patients was 55 years (range, 36 to 79 years), with only five patients younger than 50 years at the time of cancer resection. Of the two individuals in whom germline line mutations were identified from research samples only, one (man age 78 years; T3N0M0 rectal cancer) requested disclosure of his research results, and the other (woman age 38 years) declined disclosure of her results to herself and others (Table 4 ).
Extent and Impact of Not Undertaking Germline Testing
Nearly half of patients (112 of 245; 46%), including 50 (54.9%) of 91 high-likelihood patients, fully undertook germline testing (ie, gave blood and consented to receive results; Table 5 ). Some did not consent to germline testing (51 of 245; 21%); others did not provide a sample (51 of 245; 21%) or provided a sample but chose not to be informed of the results (31 of 245; 13%). The results from this latter group were included in the analysis. Hence, sample results were available for 143 (58%) of 245 patients (Table 5) . Patients who chose not to undergo germline testing were older (proportion of patients age Ͼ 70 years, 87.8% v 61.5% in those who underwent testing). There were no differences in sex, presence of right-sided tumors, or Lynch syndrome likelihood between the two groups.
For the remainder of patients (n ϭ 102), the proportions with deleterious germline mutations of MMR genes were estimated using logistic regression. The estimated proportion of germline mutations was 5.5% (95% CI, 2.1% to 17.4%), compared with 8.4% (95% CI, 4.4% to 14.2%) in those who did provide a sample (observed). The disparity between the observed and estimated germline mutations is likely the result of the differences in age between these groups. On the basis of our estimations, approximately six germline mutations were missed because either patients did not to take up the offer of germline testing (n ϭ 5.3) or, in one patient case, the individual asked not to be informed of the test results. Thus, one third of germline mutations were missed. However, as expected, there is considerable uncertainty surrounding the forecasts (Table 5) .
DISCUSSION
This study shows that the decisions or circumstances of patients as well as health professionals significantly reduce detection rates of Lynch syndrome by universal MMRD screening of incident CRCs. Nearly half of all individuals in the high-likelihood group did not undertake germline testing or declined to be informed of their results. On the basis of forecasts using available data, this meant one third of all Lynch syndrome cases were likely to be missed.
The rate of undergoing germline testing in this study is lower than those in previous clinical trials of molecular screening for Lynch syndrome. 4, 31 There are several possible reasons for this discrepancy. First, this study reports all patient cases of MMRD CRC, irrespective of patients' decision to participate. One fifth of patients in this study did not or could not consent at the point of first contact, probably reflecting the real-world setting in which this study was conducted. It was clinicians, rather than trialists or researchers, who provided information to patients. Patients could initiate actions at a time and place of their choosing, and indeed, most returned their consent more than 6 months after surgery. Also, patients were included in the study irrespective of their willingness to provide a biologic sample, resulting in an additional 20% undertaking germline testing. Finally, another 13% of participants declined to receive test information despite being fully informed of the implications of the results for themselves and their relatives. This unwillingness to receive test results not only limited the effectiveness of the screening program but is pertinent to the current debate about informing research participants of results from wholegenome testing. 32 Although we did not explore the rationale for the decisions of individual patients, previous reports have found that participants from population-based screening programs such as this are less willing to adopt testing because they are older, have more comorbidities, and are more disconnected from the beneficiaries of testing.
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Decisions of health professionals were less influential in reducing the detection rates. As primary referrers to genetic testing, it was disappointing that surgeons referred fewer than half of their patients with high-likelihood cancers, despite positive recommendations to do so. Failure to refer such patients was associated with increased patient age and left-sided tumor location, and as a consequence, one patient with Lynch syndrome who wished to know the test results remained undetected. Although superficially reassuring, we cannot explain how this selective referral of high-likelihood patients missed only one case of Lynch syndrome. Without a clear understanding of the clinical judgments informing these decisions or further research on this point, it remains important that surgeons are actively encouraged to refer all high-likelihood patients. Likewise, clinical geneticists proved effective 
‫ء‬
Using logistic regression model. †Reason for nonconsent included: lost to follow-up (but known to be alive; n ϭ 13); declined (n ϭ 18); unable for various reasons including dementia, schizophrenia, or language difficulty (n ϭ 8); or deceased (n ϭ 12).
as gatekeepers to germline testing in that they did not refuse testing to any individual with potential Lynch syndrome.
This study has a number of strengths. It was population based and undertaken within an ethnically and socioeconomically diverse health region across various clinical practice settings. In this population, we estimated 7.1% of individuals with an MMRD cancer had an underlying germline defect, consistent with previous populationbased screening studies of similar size (4% to 17%). 3, 4, 31 We found mutations of MSH6 to be most common, rather than MSH2 or MLH1 mutations, as previously reported. 4, 33 One explanation may be that a truly population-based screening approach is more likely to identify mutations such as MSH6, which are of lower penetrance or may cause disease later in life. 34 Other strengths were the use of BRAF mutation analysis as an adjunct to MMR immunohistochemistry 33, 35 and performance of germline testing on every patient sample, irrespective of molecular risk status. Because of this, we could confirm the importance of V600E BRAF mutations as markers of those individuals with MLH1-negative tumors who were at low likelihood of having Lynch syndrome. Notably, our surgeons almost universally adhered to recommendations against referral of low-likelihood patients, despite them having MMRD cancers. Finally, the design of this study, while providing some decision support, allowed health care providers and patients to behave and interact in their usual manner and timeframe and within existing resource constraints. Thus, the findings are likely to better represent real-world outcomes of a Lynch syndrome screening strategy.
The study also has limitations. It did not formally assess the performance of pathologists as screeners for Lynch syndrome. However, quality assurance found no evidence of false negatives, and our MMRD frequency (11.7%) was consistent with previous reports. 4, 5, 35, 36 Furthermore, we do not know the germline status of the 102 individuals who either did not consent or did not provide biologic samples. These nonconsenting individuals were older than other participants. However, we were still able to estimate the frequency of Lynch syndrome because of access to relevant clinicopathologic and molecular data. Finally, we did not extend our observations to the uptake of cascade testing or to compliance with surveillance, nor did we consider the implications of UCV.
This study found that a universal screening strategy for Lynch syndrome is potentially effective and was well supported by informed surgeons. However, its true value is limited by the circumstances and decisions of patients with regard to undertaking of germline testing. These findings have implications for the actual clinical benefit that will accrue from the coming wave of gene-based predisposition tests.
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